The Global Calcium Phosphate Cement (CPC) Market was valued at USD 480 Million in 2024 and is projected to reach USD 760 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period (2024–2032). This growth is being driven by rising demand for bioactive bone grafting materials, an aging global population requiring orthopedic interventions, and the accelerating adoption of advanced CPC formulations across dental and orthopedic surgery sectors worldwide.

As the biomaterials industry transforms toward more biocompatible, minimally invasive, and clinically effective solutions, the spotlight is on the key manufacturers who are driving innovation, expanding production capacity, and pioneering next-generation formulations. In this blog, we profile the Top 10 Companies in the Calcium Phosphate Cement Industry—a mix of global medical device giants, specialized biomaterial producers, and regional leaders shaping the future of bone repair technology.

---

🕁 1. Johnson & Johnson Medical Devices

Headquarters: New Brunswick, New Jersey, USA
Key Offering: Hydroxyapatite-based CPC, Bone Graft Substitutes, Orthopedic Biomaterials

Johnson & Johnson Medical Devices is among the world’s foremost players in the calcium phosphate cement market, offering a comprehensive portfolio of bone graft and biomaterial solutions for orthopedic and dental applications. The company’s CPC products are widely used in spinal fusion, trauma repair, and periodontal reconstruction procedures. With an extensive global distribution network and deep clinical partnerships, J&J maintains leadership across North America and Europe.

Innovation Initiatives:

• Continued investment in hydroxyapatite-based CPC formulations with enhanced osseointegration

• Strategic acquisitions in the biomaterials sector to broaden bone graft substitute offerings

• Clinical trial programs supporting evidence-based adoption of next-generation CPC products

Download FREE Sample Report:
Calcium Phosphate Cement (CPC) Market – View in Detailed Research Report

---

9️⃣ 2. Hoya Corporation

Headquarters: Tokyo, Japan
Key Offering: Apaceram® Hydroxyapatite, Synthetic Bone Graft Materials

Hoya Corporation is one of Asia-Pacific’s most dominant CPC manufacturers, holding a significant portion of the regional market alongside Shanghai Rebone. Hoya’s Apaceram® product line is a well-established hydroxyapatite-based ceramic widely used in orthopedic and dental reconstructive surgeries. The company benefits from decades of materials science expertise and robust manufacturing infrastructure across Japan and other Asian markets.

Innovation Initiatives:

• Development of porous hydroxyapatite scaffolds for improved vascularization and bone ingrowth

• Expansion of product lines targeting minimally invasive spinal procedures

• Partnerships with hospitals and research institutes across the Asia-Pacific region

---

8️⃣ 3. Shanghai Rebone Biomaterials Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Injectable CPC, Hydroxyapatite Bone Cement, Bone Repair Materials

Shanghai Rebone is China’s leading calcium phosphate cement manufacturer and one of the top CPC producers in the Asia-Pacific region. Together with Hoya, it collectively commands over 70% of the Asia-Pacific CPC market as of 2024. The company’s injectable CPC products are particularly popular in high-volume orthopedic procedures, and its cost-competitive pricing model has made it the supplier of choice across Chinese hospitals and emerging markets throughout Southeast Asia.

Innovation Initiatives:

• Proprietary injectable CPC formulations optimized for vertebroplasty and kyphoplasty procedures

• Scaling production capacity to meet growing domestic and international demand

• Active R&D programs in composite CPC with drug delivery capabilities

---

7️⃣ 4. Stryker Corporation

Headquarters: Kalamazoo, Michigan, USA
Key Offering: HydroSet™ Injectable HA Bone Substitute, Orthopedic Bone Repair Solutions

Stryker is a global leader in medical devices and orthopedic solutions, with a strong presence in the CPC segment through its HydroSet™ Injectable HA Bone Substitute. This product is specifically designed for the repair of osseous defects and has gained wide clinical acceptance in the United States and internationally. Stryker’s deep penetration into hospital networks and established relationships with orthopedic surgeons give it a meaningful competitive edge in the premium CPC segment.

Innovation Initiatives:

• Ongoing development of faster-setting CPC formulations for use in time-sensitive trauma procedures

• Integration of CPC products into broader bone management and fracture repair systems

• Investment in clinical education programs to support broader adoption of injectable bone substitutes

Download FREE Sample Report:
Calcium Phosphate Cement (CPC) Market – View in Detailed Research Report

---

6️⃣ 5. Zimmer Biomet Holdings, Inc.

Headquarters: Warsaw, Indiana, USA
Key Offering: Calcium Phosphate Bone Void Fillers, Orthopedic Reconstructive Solutions

Zimmer Biomet is a premier orthopedic company with a diversified bone repair portfolio that includes calcium phosphate-based void fillers and grafting materials. The company serves surgeons across joint reconstruction, spine, and trauma segments, with its CPC offerings integrated into comprehensive surgical systems. Zimmer Biomet’s established presence in over 100 countries gives it unparalleled reach in delivering advanced biomaterial solutions to both developed and emerging healthcare markets.

Innovation Initiatives:

• Development of resorbable CPC formulations tailored for long-term bone regeneration outcomes

• Strategic collaboration with academic medical centers on next-generation bone substitute research

• Portfolio expansion in minimally invasive orthopedic applications

---

5️⃣ 6. Medtronic plc

Headquarters: Dublin, Ireland
Key Offering: Calcium Phosphate Bone Grafts, Spinal Fusion Biomaterials

Medtronic is one of the world’s largest medical device companies, and its spine and biologics division actively markets calcium phosphate-based grafting materials for spinal fusion and related procedures. The company’s global manufacturing capabilities and regulatory expertise allow it to bring CPC products to market across multiple jurisdictions efficiently. Medtronic’s emphasis on integrated surgical solutions positions its CPC offerings as part of broader procedural workflows rather than standalone products.

Innovation Initiatives:

• Combination of CPC with biologic agents such as bone morphogenetic proteins (BMPs) for enhanced fusion rates

• Digital surgical planning tools that incorporate bone graft volume calculations for CPC dosing

• Expanding CPC product registrations across Asia-Pacific and Latin American markets

---

4️⃣ 7. Kyungwon Medical Co., Ltd.

Headquarters: Seongnam, South Korea
Key Offering: Injectable Calcium Phosphate Cement, Bone Repair Biomaterials

Kyungwon Medical is a South Korean specialist in calcium phosphate cement products, with a particular focus on the clinically dominant 3mL–6mL dosage segment that represents approximately 50% of Asia-Pacific market volumes. The company has significantly increased its production output since 2022, responding to heightened demand from hospitals across South Korea, China, and Southeast Asia. Its injectable CPC products are recognized for reliable handling characteristics and consistent clinical outcomes in medium-sized orthopedic and dental procedures.

Innovation Initiatives:

• Capacity expansion to meet growing regional demand for mid-range CPC dosage formats

• Product development in anti-washout CPC formulations for use in wet surgical environments

• Export market diversification into Southeast Asian and Middle Eastern healthcare systems

Download FREE Sample Report:
Calcium Phosphate Cement (CPC) Market – View in Detailed Research Report

---

3️⃣ 8. Maxigen Biotech Inc.

Headquarters: New Taipei City, Taiwan
Key Offering: OstiCure® Injectable Calcium Phosphate Cement, Bone Void Fillers

Maxigen Biotech is a Taiwan-based biomaterials company that has established a strong reputation in the Asia-Pacific CPC market through its OstiCure® product line. The company’s injectable CPC formulations are designed for ease of use in minimally invasive procedures, offering surgeons a reliable and biocompatible option for filling bone voids resulting from trauma, tumor resection, or degenerative disease. Maxigen has expanded its market reach significantly through targeted partnerships with distributors across Asia and Europe.

Innovation Initiatives:

• Development of nano-hydroxyapatite-enhanced CPC variants for superior osteoconductivity

• Pursuit of CE mark certification to strengthen European market access

• Collaboration with university research programs on antibiotic-loaded CPC formulations

---

2️⃣ 9. Biocomposites Ltd.

Headquarters: Keele, Staffordshire, United Kingdom
Key Offering: Cerament® Bone Void Filler, Calcium Sulphate/Hydroxyapatite Composites

Biocomposites is a UK-based specialist in synthetic bone graft materials, best known for its Cerament® product family, which combines calcium sulphate and hydroxyapatite in an injectable format. The company has carved out a distinct niche in the CPC-adjacent market by offering composite formulations that combine the resorption benefits of calcium sulphate with the osteoconductive properties of hydroxyapatite. Its products are used globally in trauma, orthopedic oncology, and periprosthetic infection management.

Innovation Initiatives:

• Clinical development of antibiotic-loaded composite bone void fillers for infection management

• Expanding clinical evidence base through multicenter studies across Europe and North America

• Portfolio growth targeting the management of chronic osteomyelitis and periprosthetic joint infection

---

1️⃣ 10. Zimmer Biomet / DePuy Synthes (Bone Biologics Division)

Headquarters: Raynham, Massachusetts, USA (DePuy Synthes); Warsaw, Indiana, USA (Zimmer Biomet)
Key Offering: Norian™ CRS Bone Substitute, Calcium Phosphate Grafting Systems

DePuy Synthes, a Johnson & Johnson company, brings decades of legacy in calcium phosphate bone substitutes through its Norian™ CRS (Carbonated Calcium Phosphate) bone substitute system, which has been used in thousands of orthopedic trauma and reconstructive procedures worldwide. This product converts to carbonated apatite in vivo—chemically similar to natural bone mineral—enabling genuine osseous integration. The platform’s clinical track record across tibial plateau fractures and distal radius repairs has made it one of the most documented CPC solutions in the medical literature.

Innovation Initiatives:

• Advancing CPC formulations compatible with load-sharing fixation constructs in trauma surgery

• Post-market clinical follow-up studies demonstrating long-term remodeling and resorption profiles

• Integration of CPC bone substitutes with digital surgical planning platforms for precise defect filling

Get Full Report Here:
Calcium Phosphate Cement (CPC) Market – View in Detailed Research Report

---

🌎 Outlook: The Future of Calcium Phosphate Cement Is Smarter, Stronger, and More Bioactive

The calcium phosphate cement market is undergoing a significant evolution. While traditional hydroxyapatite-based formulations continue to dominate in volume, the industry is channeling substantial investment into next-generation composite materials, drug-eluting CPC systems, and 3D-printable bone substitute technologies that promise to redefine clinical outcomes in orthopedic and dental surgery.

📈 Key Trends Shaping the Market:

• Rapid development of injectable and anti-washout CPC formulations for minimally invasive procedures

• Growing clinical adoption of antibiotic-loaded and growth factor-enriched CPC variants

• Expansion of 3D-printable CPC composites for patient-specific implant applications

• Increasing regulatory approvals and reimbursement coverage accelerating market penetration in Asia-Pacific

Get Full Report Here:
Calcium Phosphate Cement (CPC) Market – View in Detailed Research Report

The companies profiled above are not only repairing bones across the globe—they’re leading the biomaterial revolution that is transforming how surgeons restore structure, function, and quality of life for millions of patients each year.